Snake bites are a major concern worldwide, causing up to 137,000 deaths annually along with numerous amputations and disabilities. Currently, antivenoms are specific to individual snake species and are derived from antibodies from animals like sheep or horses. However, these traditional antivenoms can lead to severe side effects and require the identification of the snake responsible for the bite before treatment can be administered.
In a groundbreaking development, researchers at Centivax in San Francisco, California, led by Jacob Glanville, have made significant progress towards developing a universal snake antivenom. By harnessing antibodies from a hyperimmune individual who had been bitten by multiple snake species, the team identified two promising antibodies, LNX-D09 and SNX-B03, along with a toxin inhibitor called varespladib.
Testing on mice exposed to venom from 19 of the most dangerous snake species, including cobras and taipans, showed that the treatment provided full protection against 13 species and partial protection against six others. This discovery raises hopes for a universal snake antivenom that could potentially cover a wide range of venomous snakes.
The next phase of research will involve testing the treatment on animals brought to vet clinics in Australia after snake bites and exploring antibodies that offer coverage against viper species as well. Tian Du from the University of Sydney, Australia, expressed optimism about the potential of this universal treatment, emphasizing the importance of further studies to determine its efficacy in preventing necrosis of the skin and muscles, a common complication of snake bites.
The development of a universal snake antivenom holds great promise in revolutionizing the treatment of snake bites worldwide, potentially saving countless lives and reducing long-term disabilities associated with these incidents. With ongoing research and advancements in biotechnology, the possibility of a universal solution to snake envenoming may soon become a reality.
